Laboratory of Health Economics, Institute of Applied Economic Studies, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia.
Center for Advanced Financial Planning, Macroeconomic Analysis and Financial Statistics, Financial Research Institute of the Ministry of Finance of the Russian Federation, Moscow, Russia.
BMC Med. 2022 Jul 6;20(1):244. doi: 10.1186/s12916-022-02448-4.
Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors.
Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge.
One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47).
Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.
先前评估成人和儿童 COVID-19 后遗症患病率的研究是在缺乏共识定义的情况下进行的。我们调查了先前住院的成人和儿童在 COVID-19 后出现的疾病(PCC)(世卫组织定义)的患病率,在出院后 6 个月和 12 个月进行随访,并评估了危险因素。
这是一项在莫斯科进行的前瞻性队列研究,纳入了 2020 年 4 月至 8 月期间确诊 COVID-19 的住院儿童和成人。出院后 6 个月和 12 个月进行了两次国际严重急性呼吸和新兴感染联盟调查的电话随访。
2509 名成人中有 1013 名(40%)和 849 名儿童中有 360 名(42%)参加了 6 个月和 12 个月的随访。成人 6 个月时 PCC 的患病率为 50%(95%CI 47-53),儿童为 20%(95%CI 16-24),12 个月时分别下降至 34%(95%CI 31-37)和 11%(95%CI 8-14)。在成人中,女性在 6 个月和 12 个月的随访时与 PCC 相关(OR 2.04,95%CI 1.57-2.65)和(OR 2.04,1.54-2.69)。在 12 个月时,高血压(OR 1.42,1.04-1.94)与 COVID-19 后疾病相关。在儿童中,6 个月时(OR 4.38,1.36-15.67)和 12 个月时(OR 8.96,2.55-34.82),神经系统合并症与 PCC 相关,而过敏呼吸道疾病与 12 个月时相关(OR 2.66,1.04-6.47)。
尽管出院后一年 PCC 的患病率有所下降,但仍有三分之一的成年人和十分之一的儿童存在持续的后遗症。在成人中,女性和患有高血压的人,以及儿童中有神经系统合并症或过敏呼吸道疾病的人,患 PCC 的风险更高。